Eli Lilly’s experimental pill, orforglipron, helped patients lose approximately 11% of their body weight in a late-stage study, which falls short of expectations. The results are significant as the pill is set to enter the obesity market next year, but investors had hoped for more substantial weight loss comparable to Novo Nordisk’s blockbuster shot Wegovy.
Source: https://www.bloomberg.com/news/articles/2025-08-07/lilly-s-obesity-pill-cut-body-weight-by-11-in-key-study